Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - AT&S, Do&Co, Sanochemia (23/10/2018)

23.10.2018

AT&S: AT&S, a leading high tech PCB company, has increased the forecast for revenue and earnings. The very good business development is essentially attributable to higher revenue from the plants in Chongqing, which were in part still in the start-up phase in the previous year, as well as to measures to improve efficiency and productivity, the company stated. In addition, the superior product portfolio for IC substrates (for example server applications) contributes to the increase in earnings. As a result, AT&S now has the following expectations for the financial year 2018/19: based on stable exchange rates, the management expects revenue growth of 6 to 8% (previously up to 6%) and an EBITDA margin in the range of 24 to 26% (previously up to 23%) for the financial year 2018/19.
AT&S: weekly performance: 5.73%

Do&Co: Austrian well known catering company Do&Co announced that it has agreed with Türk Havayolları A.O. to extend the cooperation through the joint company THY DO&CO İkram Hizmetleri A.Ş. for further 15 years subject to board and regulatory approvals and satisfactory documentation.
DO&CO: weekly performance: -1.28%

Sanochemia: Sanochemia Pharmazeutika AG, an Austrian company that focuses on the development and manufacture of novel drugs and diagnostics in selected indication areas, announced that the United States Patent and Trademark Office has issued “Notice of Allowance“ for Vidon® in Photodynamic Therapy (PDT) of bladder cancer. Vidon® (PVP-Hypericin) is one of Sanochemia`s promising pipeline products and is being developed as a game changing technology in the management of bladder cancer. The patent covers the method for therapy of bladder cancer with Sanochemia’s developed PVP-Hypericin formulation. The U.S. patent will protect Vidon® until 2035.  “The Notice of Allowance for the US application of Vidon® for PDT is an important milestone to secure the long-term value of Vidon® for Sanochemia”, said Christina Abrahamsberg, CSO of Sanochemia Pharmazeutika AG.
Sanochemia: weekly performance: 7.69%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (23/10/2018)


Partners









latest 21st Austria

21st Austria weekly - AT&S, Do&Co, Sanochemia (23/10/2018)


23.10.2018, 2122 Zeichen



AT&S: AT&S, a leading high tech PCB company, has increased the forecast for revenue and earnings. The very good business development is essentially attributable to higher revenue from the plants in Chongqing, which were in part still in the start-up phase in the previous year, as well as to measures to improve efficiency and productivity, the company stated. In addition, the superior product portfolio for IC substrates (for example server applications) contributes to the increase in earnings. As a result, AT&S now has the following expectations for the financial year 2018/19: based on stable exchange rates, the management expects revenue growth of 6 to 8% (previously up to 6%) and an EBITDA margin in the range of 24 to 26% (previously up to 23%) for the financial year 2018/19.
AT&S: weekly performance: 5.73%

Do&Co: Austrian well known catering company Do&Co announced that it has agreed with Türk Havayolları A.O. to extend the cooperation through the joint company THY DO&CO İkram Hizmetleri A.Ş. for further 15 years subject to board and regulatory approvals and satisfactory documentation.
DO&CO: weekly performance: -1.28%

Sanochemia: Sanochemia Pharmazeutika AG, an Austrian company that focuses on the development and manufacture of novel drugs and diagnostics in selected indication areas, announced that the United States Patent and Trademark Office has issued “Notice of Allowance“ for Vidon® in Photodynamic Therapy (PDT) of bladder cancer. Vidon® (PVP-Hypericin) is one of Sanochemia`s promising pipeline products and is being developed as a game changing technology in the management of bladder cancer. The patent covers the method for therapy of bladder cancer with Sanochemia’s developed PVP-Hypericin formulation. The U.S. patent will protect Vidon® until 2035.  “The Notice of Allowance for the US application of Vidon® for PDT is an important milestone to secure the long-term value of Vidon® for Sanochemia”, said Christina Abrahamsberg, CSO of Sanochemia Pharmazeutika AG.
Sanochemia: weekly performance: 7.69%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (23/10/2018)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S12/13: Carola Bendl-Tschiedel




 

Bildnachweis

Aktien auf dem Radar:Polytec Group, Immofinanz, Palfinger, Warimpex, Flughafen Wien, Austriacard Holdings AG, EVN, Rosgix, S Immo, Erste Group, Österreichische Post, Cleen Energy, Marinomed Biotech, Pierer Mobility, RBI, Addiko Bank, SW Umwelttechnik, Oberbank AG Stamm, Agrana, Amag, CA Immo, Kapsch TrafficCom, OMV, Telekom Austria, Uniqa, VIG, Wienerberger, Mercedes-Benz Group, Siemens Energy, Deutsche Post, Allianz.


Random Partner

VIG
Die Vienna Insurance Group (VIG) ist mit rund 50 Konzerngesellschaften und mehr als 25.000 Mitarbeitern in 30 Ländern aktiv. Bereits seit 1994 notiert die VIG an der Wiener Börse und zählt heute zu den Top-Unternehmen im Segment “prime market“ und weist eine attraktive Dividendenpolitik auf.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten